← All companies ← DXC Manual DXPE → ← DRIO Medical Devices & Equipment ELMD →
DXCM, DexCom Inc.
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.
We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006.
We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 65% and operating margin about 12% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −18% to 20% — on a steadier 65% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Capital spending runs about 9.2% of sales, well above depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the installed base and what follows it. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has sat near the cost of capital (median 10%). By owner earnings: roughly 17% of revenue reaches owners as cash, consistently. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 10-K →28% of revenue comes from outside the United States.
- United States72%$3.3B
- International28%$1.3B
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
Revenue up 13.1% year over year; operating income up 49.7%
figures computed from the filing's XBRL
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $573M | $719M | $1.0B | $1.5B | $1.9B | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B | $5.0B | RevenueRevenue |
| $378M | $492M | $664M | $932M | $1.3B | $1.7B | $1.9B | $2.3B | $2.4B | $2.8B | $3.1B | Gross profitGross prof. |
| 66% | 68% | 64% | 63% | 66% | 69% | 65% | 63% | 60% | 60% | 62% | Gross marginGross mgn |
| 50% | 49% | 42% | 35% | 32% | 33% | 35% | 33% | 32% | 28% | 27% | SG&A / revenueSG&A/rev |
| 27% | 26% | 19% | 19% | 19% | 21% | 17% | 14% | 14% | 13% | 12% | R&D / revenueR&D/rev |
| ($64M) | ($43M) | ($186M) | $142M | $300M | $266M | $391M | $598M | $600M | $912M | $1.1B | Operating incomeOp. inc. |
| −11.1% | −5.9% | −18.1% | 9.6% | 15.5% | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% | 22.9% | Operating marginOp. mgn |
| ($65M) | ($49M) | ($127M) | $104M | $298M | $257M | $391M | $710M | $709M | $1.1B | — | Pretax incomePretax |
| ($66M) | ($50M) | ($127M) | $101M | $550M | $217M | $341M | $542M | $576M | $836M | $1000M | Net incomeNet inc. |
| — | — | — | 3% | — | 16% | 13% | 24% | 19% | 23% | 22% | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| $56M | $92M | $123M | $315M | $476M | $443M | $670M | $749M | $990M | $1.4B | $1.7B | Operating cash flowOp. cash |
| $15M | $16M | $29M | $49M | $67M | $102M | $156M | $186M | $218M | $252M | $264M | DepreciationDeprec. |
| ($4M) | $20M | $119M | $62M | ($261M) | $10M | $46M | ($130M) | $25M | $193M | $323M | Working capital & otherWC & other |
| $56M | $66M | $67M | $180M | $199M | $389M | $365M | $237M | $359M | $364M | $344M | CapexCapex |
| 9.7% | 9.2% | 6.5% | 12.2% | 10.3% | 15.9% | 12.5% | 6.5% | 8.9% | 7.8% | 6.9% | Capex / revenueCapex/rev |
| $41M | $76M | $94M | $266M | $409M | $341M | $514M | $563M | $772M | $1.2B | $1.5B | Owner earningsOwner earn. |
| 7.2% | 10.6% | 9.1% | 18.0% | 21.2% | 13.9% | 17.7% | 15.5% | 19.1% | 25.5% | 29.9% | Owner earnings marginOE mgn |
| $500K | $26M | $56M | $135M | $277M | $53M | $305M | $512M | $631M | $1.1B | $1.4B | Free cash flowFCF |
| 0.1% | 3.6% | 5.4% | 9.1% | 14.4% | 2.2% | 10.5% | 14.1% | 15.6% | 23.1% | 28.3% | Free cash flow marginFCF mgn |
| $0 | $0 | $11M | $0 | $0 | $30M | $4M | $0 | $0 | — | $0 | AcquisitionsAcquis. |
| $0 | $0 | $100M | $0 | $0 | $0 | $558M | $689M | $750M | $500M | — | BuybacksBuybacks |
| ($56M) | ($144M) | ($140M) | ($1.0B) | ($1.0B) | ($216M) | ($522M) | ($507M) | ($208M) | $536M | — | Investing cash flowInv. cash |
| $8M | $399M | $710M | $11M | $912M | $10M | ($553M) | ($319M) | ($735M) | ($1.7B) | — | Financing cash flowFin. cash |
| $0 | $300K | $2M | ($700K) | $2M | ($1M) | ($6M) | $2M | ($7M) | $22M | — | Exchange-rate effectFX |
| $8M | $347M | $696M | ($691M) | $372M | $235M | ($410M) | ($76M) | $40M | $312M | — | Change in cashΔ cash |
| -27% | -11% | -27% | 9% | 10% | 8% | 13% | 12% | 18% | 23% | 32% | ROICROIC |
| -23% | -12% | -19% | 11% | 30% | 11% | 16% | 26% | 27% | 30% | 38% | Return on equityROE |
| −23% | −12% | −19% | 11% | 30% | 11% | 16% | 26% | 27% | 30% | 38% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $124M | $549M | $1.1B | $446M | $818M | $1.1B | $642M | $566M | $606M | $918M | $1.4B | Cash & investmentsCash+inv |
| $102M | $134M | $227M | $286M | $429M | $514M | $713M | $974M | $1.0B | $1.2B | $1.3B | ReceivablesReceiv. |
| $45M | $45M | $71M | $120M | $235M | $357M | $307M | $560M | $543M | $629M | $726M | InventoryInvent. |
| $41M | $47M | $76M | $102M | $163M | $189M | $238M | $276M | $345M | $344M | $424M | Accounts payablePayables |
| $106M | $133M | $222M | $304M | $500M | $682M | $782M | $1.3B | $1.2B | $1.5B | $1.6B | Operating working capitalOper. WC |
| $280M | $745M | $1.7B | $2.0B | $3.4B | $3.7B | $3.7B | $4.4B | $4.3B | $4.0B | $4.1B | Current assetsCur. assets |
| $102M | $139M | $222M | $360M | $614M | $721M | $1.8B | $1.6B | $2.9B | $2.1B | $2.4B | Current liabilitiesCur. liab. |
| 2.7× | 5.4× | 7.6× | 5.5× | 5.6× | 5.1× | 2.0× | 2.8× | 1.5× | 1.9× | 1.7× | Current ratioCurr. ratio |
| $109M | $146M | $183M | $321M | $515M | $802M | $1.1B | $1.1B | $1.3B | $1.6B | — | Net PP&ENet PP&E |
| $11M | $12M | $19M | $19M | $19M | $27M | $26M | $25M | $23M | $24M | $24M | GoodwillGoodwill |
| $403M | $904M | $1.9B | $2.4B | $4.3B | $4.9B | $5.4B | $6.3B | $6.5B | $6.3B | $6.5B | Total assetsAssets |
| $0 | $328M | $1.0B | $1.1B | $2.0B | $2.0B | $1.2B | $2.4B | $1.2B | $1.2B | $1.2B | Total debtDebt |
| ($124M) | ($221M) | ($127M) | $614M | $1.2B | $929M | $555M | $1.9B | $631M | $323M | ($113M) | Net debt / (cash)Net debt |
| -91.3× | -3.3× | -8.2× | 2.4× | 16.9× | 14.1× | 21.0× | 29.4× | 31.6× | 49.8× | 75.9× | Interest coverageInt. cov. |
| $119M | $485M | $1.3B | $1.5B | $2.5B | $2.9B | $3.3B | $4.2B | $4.4B | $3.6B | — | Total liabilitiesTotal liab. |
| $284M | $419M | $663M | $883M | $1.8B | $2.0B | $2.1B | $2.1B | $2.1B | $2.7B | $2.6B | Shareholders’ equityEquity |
| 19.3% | 14.8% | 9.9% | 7.0% | 6.2% | 4.6% | 4.3% | 4.2% | 4.2% | 3.4% | 3.3% | Stock comp / revenueSBC/rev |
| Per share | |||||||||||
| 83.6M | 86.3M | 88.2M | 92.3M | 420M | 429M | 428M | 426M | 413M | 406M | 392M | Shares out (diluted)Shares |
| $6.86 | $8.33 | $11.70 | $15.99 | $4.58 | $5.71 | $6.81 | $8.51 | $9.77 | $11.50 | $12.68 | Revenue / shareRev/sh |
| $-0.78 | $-0.58 | $-1.44 | $1.10 | $1.31 | $0.51 | $0.80 | $1.27 | $1.40 | $2.06 | $2.55 | EPS (diluted)EPS |
| $0.49 | $0.88 | $1.07 | $2.88 | $0.97 | $0.79 | $1.20 | $1.32 | $1.87 | $2.93 | $3.79 | Owner earnings / shareOE/sh |
| $0.01 | $0.30 | $0.64 | $1.46 | $0.66 | $0.12 | $0.71 | $1.20 | $1.53 | $2.66 | $3.59 | Free cash flow / shareFCF/sh |
| $0.67 | $0.76 | $0.76 | $1.95 | $0.47 | $0.91 | $0.85 | $0.56 | $0.87 | $0.90 | $0.88 | Cap. spending / shareCapex/sh |
| $3.39 | $4.86 | $7.52 | $9.56 | $4.34 | $4.76 | $4.99 | $4.86 | $5.09 | $6.77 | $6.69 | Book value / shareBVPS |
The diluted share count moved ×4.55 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +5.9%/yr | +20.2%/yr |
| Owner earnings / share | +21.9%/yr | +24.7%/yr |
| EPS | — | +9.5%/yr |
| Capital spending / share | +3.4%/yr | +13.6%/yr |
| Book value / share | +8.0%/yr | +9.3%/yr |
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cashEach year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business earned $1.2B of owner earnings, the operating cash left after the $252M it takes just to hold its position. It put $112M more into growth; free cash flow, after that spending, was $1.1B.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $836M | $576M | $542M | $341M | $217M |
| Depreciation & amortizationnon-cash charge added back | +$252M | +$218M | +$186M | +$156M | +$102M |
| Stock-based compensationreal costnon-cash, but a real cost | +$160M | +$170M | +$151M | +$127M | +$113M |
| Working capital & othertiming of cash in and out, other non-cash items | +$193M | +$25M | −$130M | +$46M | +$10M |
| Cash from operations | $1.4B | $990M | $749M | $670M | $443M |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −$252M | −$218M | −$186M | −$156M | −$102M |
| Owner earnings | $1.2B | $772M | $563M | $514M | $341M |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | −$112M | −$141M | −$51M | −$209M | −$287M |
| Free cash flow | $1.1B | $631M | $512M | $305M | $53M |
| Owner-earnings marginowner earnings ÷ revenue | 26% | 19% | 16% | 18% | 14% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $252M, roughly its depreciation, the rate its assets wear out). The other $112M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $160M), owner earnings is nearer $1.0B.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? 49.8×ComfortableOperating income $912M ÷ interest expense $18M
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- How heavy is the debt, net of cash? $323M · 0.4× operating profitModest net debtCash $918M − debt $1.2B
What this means
Netting $918M of cash and short-term investments against $1.2B of debt leaves $323M owed, about 0.4× a year's operating profit (1.4× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 95 + DIO 123 − DPO 68 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Solid through the cycle10-yr median, range -27%–23%; 23% latest = NOPAT $701M ÷ invested capital $3.1BIndustry peers: median 11%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 23% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- High through the cycle10-yr median margin, range 7%–26%; latest $1.2B = operating cash $1.4B − maintenance capex $252MIndustry peers: median 14%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 26% of revenue this year, a 17% median across 10 years. Treating stock comp as the real expense it is (less $160M of SBC) leaves $1.0B.
- Cash-backedCash from ops $1.4B ÷ net income $836M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Returns about halfDividends + buybacks $500M ÷ Owner Earnings $1.2B — this fiscal year
What this means
Of $1.2B Owner Earnings, $500M (42%) went back to shareholders, $0 dividends, $500M buybacks. Net of $160M stock comp, the real buyback was about $340M. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does. This year's proportion is 42%; across the record (2016–2025) it is 61%, the capital-allocation section below.
- Investing or harvesting? 1.44×ExpandingCapex $364M ÷ depreciation $252M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 3.4%The count is genuinely shrinkingStock compensation $160M (fiscal 2025), 3.4% of revenue · repurchases $500M · diluted shares -5.1% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 2 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size PassRevenue ≥ $2B · $4.7B
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity NearCurrent ratio ≥ 2× · 1.88×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $1.2B vs $1.9B WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 3 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $1.73/share (latest year $2.22), the averaged base the calculator's gate runs on, and book value is $7.28/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 7 of 10
What this means
Lost money in 3 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 2 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin −12% → 17% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about −12% early to 17% lately, median 11% — pricing power intact or improving.
- Reinvestment, incremental ROIC 22%
What this means
Every extra dollar the business reinvested came back at a high incremental return — the lens GBM read for a moat that reinvests rather than merely harvests. The record and the 10-K are where you check whether the rate holds.
- Owner earnings growth +37%/yr
What this means
Owner earnings grew about 37% a year over the record.
- Worst year 2018 · −18.1% op. margin
What this means
Operations went underwater in 2018, understand why before trusting the good years.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Jun 30, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$1.4B
- Receivables$1.3B
- Inventory$726M
- Other current assets$748M
- Accounts payable$424M
- Other current liabilities$1.9B
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $5.4B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$2.3B · 43%
- Buybacks$2.6B · 49%
- Retained (debt / cash)$475M · 9%
- Returned to owners$2.6B
61% of the owner earnings the business produced over the span, $0 as dividends and $2.6B as buybacks.
- Source of fundingOperating cash
Operating cash covered reinvestment and returns; over the span debt rose $1.2B and cash and short-term investments rose $1.2B.
- Average price paid for buybacks$85.97
Across the years where the filing reports a share count, 30M shares were bought for $2.6B, about $85.97 each. Year to year the price paid ranged from $64.94 (2025) to $146.53 (2023); its heaviest year, 2024, paid $72.12 ($750M).
- Net change in share count368.7%
The diluted count rose from 84M to 392M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.
- Dividend record—
No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.
- Return on what it retained238%
Of the earnings it kept rather than paid out ($324M over the span), annual owner earnings (first three years vs last three) grew $771M, so each retained $1 added about 2.38 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|
| 2021 | $12.0M | $36.1M | $341M |
| 2022 | $15.4M | $5.7M | $514M |
| 2023 | $15.7M | $23.0M | $563M |
| 2024 | $15.8M | −$8.7M | $772M |
| 2025 | $8.0M | $6.7M | $1.2B |
| 2025 | $16.3M | $13.0M | $1.2B |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership<1%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$160M
The slice of the business handed to employees in shares in fiscal 2025, 3.4% of revenue, equal to 17.5% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Peers, Medical Devices & Equipment
The same industry, side by side on owner economics. Each column names the period it is read over; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| SOLVSolventum Corporation | $8.3B | 56% | 20.7% | 12% | 14% |
| RMDResMed Inc. | $5.1B | 57% | 27.1% | 17% | 19% |
| DXCMDexCom Inc. | $4.7B | 65% | 12.1% | 10% | 17% |
| MMEDMiniMed Group Inc. | $3.1B | 56% | -5.4% | -3% | -4% |
| WSTWest Pharmaceutical | $3.1B | 35% | 19.0% | 19% | 17% |
| GMEDGlobus Medical | $2.9B | 75% | 19.9% | 11% | 17% |
| PODDInsulet Corporation | $2.7B | 65% | 6.2% | 5% | 4% |
| ICUIICU Medical | $2.2B | 37% | 2.0% | 5% | 5% |
| Group median | — | 57% | 15.6% | 10% | 15% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what DexCom Inc. has delivered.
DexCom Inc.’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, DexCom Inc. earns about $773M on its 16.6% median owner-earnings margin. This year’s 25.5% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.68% 10-year Treasury (Jul 30, 2026) + 4.32 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.68%, as of Jul 30, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Free cash flow $1.4B on 377M shares outstanding, per the 10-Q cover, as of 2026-07-23; net cash $112M. The if-converted diluted count is 392M, 4% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. Capex ($344M) runs well above depreciation ($264M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $1.5B, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← DXC its page in the Manual DXPE →
Industry order: ← DRIO the Medical Devices & Equipment chapter ELMD →